Medicine for the Mind

In a world where the go to solution to most people's medical problems is some kind of one-size-fits-all pill, Entheon Biomedical ENTBNF is taking a more personalized approach aimed at improving treatment outcomes for patients undergoing psychedelic assisted therapeutic treatments. By working with experienced partners to develop data-driven tools to complement psychedelic assisted protocols (PAPs), Entheon is working to change the way we treat addiction disorders. Personalizing A Psychedelic Approach Current therapeutic treatments and modern day approaches to treating many mental health issues simply don't work. For example, in the realm of rehabilitation for addiction disorders, recovery rates are low and relapse rates are high. Entheon is working to invert the current addiction-recovery ratio, and turn untreatable cases from the norm into the exception. Entheon is developing a highly personalized approach to addiction treatments through their developments in psychedelic medicine and coinciding therapy. CEO Timothy Ko, points out that a system of tailored and patient-specific treatment is incredibly important, "The developing psychedelic medicine and therapy space is providing the opportunity to create a system of medicine that is highly personalized. We feel this is of the utmost importance because individuals react differently to different psychedelic molecules and many of the indications being targeted by PAP (e.g. addiction, depression, eating disorders, and PTSD) are disorders and conditions with factors that are unique to the individual." The use of psychedelics within the context of a system of personalized medicine, shows promise that treatments can be tailored to the individual in order to best target the underlying factors of their respective addiction disorder. Optimizing A New Path Entheon Biomedical is forging a new path to treatment, one that is designed to provide freedom from addiction by targeting the root cause and core mechanism of addiction disorders. Studies conducted by John Hopkins University support Entheon's missions and have already shown the potential efficacy of psychedelics combined with therapy to provide "rapid and large reductions" in depressive symptoms and have also carried out studies showing the ability for psychedelics to target and treat addiction tendencies, while providing increased openness, as well as greater emotional stability. Johns Hopkins Psychedelic Research lead, Dr. Matthew Johnson, and a long-time advisor of Entheon, is also helping guiden Entheon on the pathway to clinical success. An additional key to further developing Entheon's DMT treatment and finding ways to optimize its use is the power of data. Delving into each individual's brain patterns with the use of EEGs, as well as screening their DNA allows a further understanding of each individual profile and helps provide indication of specific genetic biomarkers that have shown correlation to adverse reactions with particular psychedelics. Being able to better understand which psychedelics work with certain people provides more predictability, and safety, to help further establish the use of hallucinogenic drugs and its coinciding scientific approach to therapy. Coming Together The recent acquisition of HaluGen Life Sciences, has provided Entheon with the resources to further advance their commitment to safety and efficacy in the application of psychedelic treatment. HaluGen has developed and is preparing to commercialize the industry's first "Psychedelics Genetic Test" which is designed to predict potential adverse reactions associated with the consumption of hallucinogenic drugs. "Our acquisition of HaluGen and partnership with Neurodivergence expands our expertise in the fields of genetics, EEG, and computational patient analysis and reflects our commitment to the scientific development of protocols, therapeutics and products that support the safe and effective delivery of psychedelic treatments," said Timothy Ko. "The tools we are developing are molecule agnostic, and while Entheon is focused on the development of DMT, we believe our therapeutic framework and intelligence platform will be applied across the emerging psychedelic medicine industry. We look forward to continuing to work with our partners to advance these initiatives and therapies to market." This commitment is also supported by Entheon's partnership with Divergence Neuro, a company focused on the research and development of a data-driven, cloud-based neuro platform based on electroencephalogram (EEG) analysis and machine learning. Together, the two companies are developing a predictive model of biomarker responses to drug dosage and delivery of psychedelic therapeutic products and a software platform that supports the tracking, analysis and use of EEG data throughout the psychedelic therapy process. This provides critical data to continue solidifying the uses of these therapies, preparing them for broad-adoption in the future. Summary The demand for a solution to addiction disorders, including the growing opioid crisis, is growing every day as many watch their loved ones suffer and become part of the ever increasing statistical nightmare. Behind the scenes, Entheon Biomedical is forging a new path, revolutionizing the way addiction disorders are treated, with the intention to effectively assist people in regaining their freedom and independence through a scientifically-validated and data-driven approach to psychedelic-assisted medicine. While some may be wary of this approach, Entheon is ensuring they provide the research and data to support their claims, as well as find partnerships to further their mission. The Centre for Human Drug Research (CHDR), a Netherlands-based contract research organization (CRO) that specializes in early-stage clinical drug research, is conducting human trials for Entheon to evaluate the pharmacodynamics, pharmacokinetics and safety of IV-administered DMT, and is expected to start in the Q4 of 2021.